-transparent.png){kind=logo}
Sequential whole-body scans with both 67Ga-citrate and 111In-bleomycin were performed for 14 patients undergoing staging for Hodgkin's disease or other lymphomas. A comparison or these scans gave a sensitivity in detecting the pathologically-proved tumor sites of 84% for 67Ga-citrate and only 56% for 111In-bleomycin. In 12 patients, the gallium scan demonstrated the lesions more clearly; in the others, the uptake of the two radionuclides was equal. In no case was a clinically diagnosed or histologically proved lesion identified by 111In-bleomycin that was not also demonstrated by 67Ga-citrate. 111In-bleomycin does not complement the 67Ga-citrate scan in the scintigraphic evaluation of lymphomas.
C Bekerman, and
E M Moran, and
P B Hoffer, and
R W Hendrix, and
A Gottschalk
January 1979,
Polski przeglad radiologii i medycyny nuklearnej,
C Bekerman, and
E M Moran, and
P B Hoffer, and
R W Hendrix, and
A Gottschalk
January 1980,
European journal of nuclear medicine,
C Bekerman, and
E M Moran, and
P B Hoffer, and
R W Hendrix, and
A Gottschalk
December 1987,
Meditsinskaia radiologiia,
C Bekerman, and
E M Moran, and
P B Hoffer, and
R W Hendrix, and
A Gottschalk
June 1978,
Radiology,
C Bekerman, and
E M Moran, and
P B Hoffer, and
R W Hendrix, and
A Gottschalk
December 1977,
Cancer,
C Bekerman, and
E M Moran, and
P B Hoffer, and
R W Hendrix, and
A Gottschalk
November 1984,
Journal of surgical oncology,
C Bekerman, and
E M Moran, and
P B Hoffer, and
R W Hendrix, and
A Gottschalk
January 1996,
Problemy tuberkuleza,
C Bekerman, and
E M Moran, and
P B Hoffer, and
R W Hendrix, and
A Gottschalk
January 1981,
Polski przeglad radiologii i medycyny nuklearnej,
C Bekerman, and
E M Moran, and
P B Hoffer, and
R W Hendrix, and
A Gottschalk
August 2003,
European journal of nuclear medicine and molecular imaging,
C Bekerman, and
E M Moran, and
P B Hoffer, and
R W Hendrix, and
A Gottschalk
January 2018,
World journal of nuclear medicine,
